You are here: Industry Insights > Ofev

News List

New products to drive systemic sclerosis market to $1.8 bn by 2030: GlobalData expresspharma
June 21, 2021
GlobalData expects Ofev and Actemra/RoActemra to reach peak global sales of $508.8 million in 2025 and $163.2 million in 2024, respectively.
SMC backs five new medicines for NHS use pharmatimes
June 09, 2021
The Scottish Medicines Consortium (SMC) has accepted five new medicines for use by NHS Scotland in its June 2021 decisions.
Ofev® (nintedanib) approved by FDA to treat interstitial lung diseases europeanpharmaceuticalreview
March 11, 2020
The FDA has granted marketing authorisation for Ofev, as the first treatment for patients with chronic fibrosing interstitial lung diseases (ILDs).
First treatment for patients with rare lung disease approved europeanpharmaceuticalreview
September 10, 2019
The FDA has approved the first treatment for interstitial lung disease associated with systemic sclerosis or scleroderma.
FDA Approves Boehringer’s Ofev contractpharma
September 10, 2019
Becomes the first and only therapy to slow the rate of decline in pulmonary function in systemic sclerosis-associated ILD.
FDA Approves Ofev (nintedanib) for Interstitial Lung Disease Associated with Systemic Sclerosis or Scleroderma (SSc-ILD) drugs
September 09, 2019
The U.S. Food and Drug Administration today approved Ofev (nintedanib) capsules to slow the rate of decline in pulmonary function in adults with interstitial lung disease associated...